Longitudinal PET Imaging of α7 Nicotinic Acetylcholine Receptors with [


Journal

Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 10 7 2019
medline: 23 2 2021
entrez: 10 7 2019
Statut: ppublish

Résumé

The nicotinic acetylcholine alpha-7 receptors (α7R) are involved in a number of neuropsychiatric and neurodegenerative brain disorders such as Parkinson's disease (PD). However, their specific pathophysiologic roles are still unclear. In this context, we studied the evolution of these receptors in vivo by positron emission tomography (PET) imaging using the recently developed tracer 3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[ PET imaging of α7R was performed at 3, 7, and 14 days following a partial striatal unilateral lesion with 6-hydroxydopamine in adult rats. After the last imaging experiments, the status of nigro-striatal dopamine neurons as well as different markers of neuroinflammation was evaluated on brain sections by autoradiographic and immunofluorescent experiments. We showed an early and transitory rise in α7R expression in the lesioned striatum and substantia nigra, followed by over-expression of several gliosis activation markers in these regions of interest. These findings support a longitudinally follow-up of α7R in animal models of PD and highlight the requirement to use a potential neuroprotective approach through α7R ligands at the early stages of PD.

Identifiants

pubmed: 31286348
doi: 10.1007/s11307-019-01400-y
pii: 10.1007/s11307-019-01400-y
doi:

Substances chimiques

3-(1,4-diazabicyclo(3.2.2)nonan-4-yl)-6-fluorodibenzo(b,d)thiophene 5,5-dioxide 0
Amphetamines 0
Azabicyclo Compounds 0
Cyclic S-Oxides 0
Fluorine Radioisotopes 0
Radiopharmaceuticals 0
alpha7 Nicotinic Acetylcholine Receptor 0
Fluorine-18 GZ5I74KB8G

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

348-357

Références

J Nucl Med. 2006 Nov;47(11):1858-66
pubmed: 17079820
Neurotox Res. 2017 Jul;32(1):71-81
pubmed: 28285346
J Med Chem. 2013 Oct 10;56(19):7574-89
pubmed: 24050653
J Neurochem. 2004 Apr;89(2):337-43
pubmed: 15056277
Stroke. 2012 Nov;43(11):3063-70
pubmed: 22933588
Neuroimage. 2018 Jan 15;165:118-124
pubmed: 28993233
Nucl Med Biol. 2014 Jan;41(1):106-13
pubmed: 24210285
J Neurosci. 1985 May;5(5):1307-15
pubmed: 3998824
Adv Exp Med Biol. 2015;827:353-65
pubmed: 25387975
Am J Transl Res. 2017 Mar 15;9(3):971-985
pubmed: 28386326
Cell Mol Life Sci. 2016 Jul;73(13):2511-30
pubmed: 26979166
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1042-1050
pubmed: 28120003
Sci Rep. 2017 Feb 27;7:43778
pubmed: 28240322
Glia. 2003 Jan 15;41(2):207-11
pubmed: 12509811
J Pharmacol Exp Ther. 1999 Nov;291(2):648-54
pubmed: 10525084
Mediators Inflamm. 2017;2017:2515408
pubmed: 28572711
Chem Commun (Camb). 2015 Oct 14;51(80):14826-31
pubmed: 26359819
Exp Neurol. 2015 Jan;263:277-84
pubmed: 25261754
Front Med (Lausanne). 2015 Sep 02;2:61
pubmed: 26389120
Trends Pharmacol Sci. 2015 Feb;36(2):96-108
pubmed: 25639674
Neuroscience. 1994 Mar;59(2):401-15
pubmed: 7516500
Pharmacol Rev. 2015 Oct;67(4):1025-73
pubmed: 26419447
Curr Drug Targets. 2012 May;13(5):594-601
pubmed: 22300025
J Neurosci. 2002 Apr 15;22(8):3061-9
pubmed: 11943809
Dis Model Mech. 2014 Sep;7(9):1101-9
pubmed: 25038061
Curr Pharm Des. 2010 Jan;16(3):323-43
pubmed: 20109142
Biochem Pharmacol. 2015 Oct 15;97(4):566-575
pubmed: 26232729
J Neuroinflammation. 2011 Dec 10;8:174
pubmed: 22152337
Biochem Pharmacol. 2018 May;151:214-225
pubmed: 29248596
Synapse. 2019 Mar;73(3):e22077
pubmed: 30368914
Int J Neuropsychopharmacol. 2018 Jul 1;21(7):656-667
pubmed: 29522184
Eur J Neurosci. 1999 Aug;11(8):2689-96
pubmed: 10457165
Behav Brain Res. 2018 Oct 15;352:133-141
pubmed: 29074404
Biochem Pharmacol. 2015 Oct 15;97(4):399-407
pubmed: 26093062

Auteurs

Steven Vetel (S)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Johnny Vercouillie (J)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.
INSERM CIC 1415, University Hospital, Tours, France.

Frédéric Buron (F)

Institut de Chimie Organique et Analytique, ICOA, UMR CNRS 7311, Université d'Orléans, Orleans, France.

Jackie Vergote (J)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Clovis Tauber (C)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Julie Busson (J)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Gabrielle Chicheri (G)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Sylvain Routier (S)

Institut de Chimie Organique et Analytique, ICOA, UMR CNRS 7311, Université d'Orléans, Orleans, France.

Sophie Sérrière (S)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France.

Sylvie Chalon (S)

UMR Inserm U1253, iBrain, Université de Tours, UFR de Médecine, 10 Boulevard Tonnellé, 37032, Tours Cedex 01, France. sylvie.chalon@univ-tours.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH